![Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. - Lancet - X-MOL Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. - Lancet - X-MOL](https://xpic.x-mol.com/20180701%2F10.1016_S1470-2045%2818%2930241-9.jpg)
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. - Lancet - X-MOL
![PDF) What's Next? Athletes Reporting Opportunities In Their Sports After Their Sport Carrier | Piroska Béki - Academia.edu PDF) What's Next? Athletes Reporting Opportunities In Their Sports After Their Sport Carrier | Piroska Béki - Academia.edu](https://0.academia-photos.com/20134980/10315887/33707096/s200_piroska.b_ki.jpg)
PDF) What's Next? Athletes Reporting Opportunities In Their Sports After Their Sport Carrier | Piroska Béki - Academia.edu
![Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. - Lancet - X-MOL Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. - Lancet - X-MOL](https://xpic.x-mol.com/20171201%2F10.1016_S1470-2045%2817%2930691-5.jpg)